Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies (SHIMMER)

Dementia with Lewy bodies (DLB) is a progressive disorder affecting thinking, movement, behavior and sleep. Because currently there are no FDA-approved treatments for DLB, developing safe and effective treatments is the #1 priority for DLB research.

What is this study about?

The purpose of this clinical trial is to learn about the safety of CT1812 and how well it is tolerated. The study will also test how well CT1812 will treat mild to moderate DLB.

What’s involved?

Study participants will attend 12 study visits over 8 months. During that time, participants will be randomly assigned to take the study drug or a placebo (a pill with no active ingredients) for six months.

Who can participate?

You may be able to participate if you are:

  • Between the ages of 50 to 85
  • Have been diagnosed with mild to moderate dementia with Lewy bodies (DLB)
  • Have a caregiver/study partner who is willing and able to attend all study visits and participate in some study assessments

Study Sites

Please contact the study site closest to you to determine if you are eligible to participate.

State City Study Site Name Study Coordinator Email and Phone Number
Arizona Phoenix Barrow Neurological Institute Jalisa Santiago 800-392-2222
Arizona Sun City Banner Sun Health Research Institute Michele Gutierrez
Arizona Tucson University of Arizona – Health Sciences Center Scott Silviu Richards
California Palo Alto Stanford University Stephanie Tran
California Santa Monica Pacific Neuroscience Institute Marisol Savage
Colorado Aurora University of Colorado Franklin Roberts, BS
Lauren McCall
Colorado Englewood Cenexel RMCR Alyssa Andreen
Connecticut Stamford New England Institute for Clinical Research Katie Nejati
Florida Boca Raton University of Miami Adolfo M. Henriquez
Florida Boca Raton Parkinson’s Disease and Movement Disorders Center of Boca Raton
561-392-1818 ext 2
Florida Ocala Renstar Medical Research Alyssa Ashley
Florida The Villages Charter Research Omar Cortes
Brittany Ortiz
Florida Winter Park Charter Research Winter Park Jessica Garaycoa
Illinois Chicago Rush University Medical Center Kat (Katheryn) Woo
Indiana Indianapolis IU School of Medicine Sarah Collins
Indiana Indianapolis JWM Neurology, P.C. Tammy Root
Kansas Fairway The University of Kansas Alzheimer’s Disease Research Center Alexandria Montero
Main Center: 913-588-0555
Ally direct: 913-574-2512
Kentucky Lexington University of Kentucky – Sanders Brown Center on Aging Keisha Jones
Massachusetts Plymouth Headlands Research Eastern MA Elaine Kearny
Minnesota Rochester Mayo Clinic Elizabeth Abrahamson
New York New York Columbia University Katrina Cuasay
North Carolina Chapel Hill UNC Department of Neurology Latorius Adams
Ohio Cleveland The Cleveland Clinic Elizabeth Irwin
Ohio Columbus The Ohio State University Emily Shalosky
Oregon Portland Oregon Health and Science University Morgan Wilhelmi
Oregon Portland Summit Headlands, LLC Aaliyah Bussanich
Texas Dallas University of Texas Southwestern Kamrin Lazenby
Texas Houston Clinical Trial Network Salvador Acevedo-Gomez
Virginia Charlottesville University of Virginia Adult Neurology Colleen Webber, CCRC
Virginia Richmond Virginia Commonwealth University Kara McHaney
Washington Kirkland Evergreen Health Research
Washington Seattle Alzheimer’s Disease Research Center, Memory Brain and Wellness Center Donovan Mason
Washington Seattle University of Washington Aasiya Islam

Study Sponsor:

Cognition Therapeutics

This study was funded by the National Institute on Aging, National Institutes of Health